Price of TAK-700
please inquire via firstname.lastname@example.org
or Fax: 1-201-884-1288(USA Fax#)
We match the lowest price on market.
TAK-700 is an oral, selective, non-steroidal androgen synthesis inhibitor of the 17,20 lyase in clinical trials.
Technical DataFormula: C18H17N3O2
CAS#: 426219-23-0 (free base), 426219-53-6 (salt)
Storage Conditions: 2ºC to 8 ºC, or -20ºC for 2 years.
ReferenceNovel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling
A Molina...- The Journal of urology, 2011 - Elsevier... with progression after docetaxel based chemotherapy. TAK-700 and TOK-001 (formerly VN124-1) are novel selective cytochrome p450 17 inhibitors that recently entered phase I/II evaluation. MDV3100 is a second generation ...
Targeting continued androgen receptor signaling in prostate cancer
C Massard... - Clinical Cancer Research, 2011 - AACRclincancerres.aacrjournals.org
... Several novel agents also targeting androgen receptor signaling are currently being evaluated, including MDV3100 and orteronel (TAK-700). ... Other Drugs. TAK-700 (Orteronel). TAK-700 is a selective, but less potent, nonsteroidal inhibitor of 17,20-lyase. ...